Vitasora Health (VHL) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
26 Dec, 2025U.S. Growth Plans and Major Deals
Recent capital raise completed, supporting expansion and operational changes to handle anticipated patient volume growth in the U.S. market.
Eight major late-stage contract negotiations underway, with potential to increase the patient pool to 350,000 Medicare patients.
New contracts signed with Evolent (NYSE-listed, 94,000–100,000 Medicare patients) and Physicians Alliance Corporation (5,000+ doctors, 30,000 test patients), both on value-based models.
Integration of Orb acquisition progressing, with $4.2 million in revenue, $2.2 million in synergy, and $1.4 million in synergies already secured, plus $1.3 million+ in upsell opportunities.
Focus on scaling operations and systems to support onboarding tens of thousands of new patients, especially in Medicare and chronic disease management.
Value-Based Healthcare and Connected Care Strategy
U.S. healthcare is shifting rapidly toward value-based contracts, with CMS aiming for all major ACOs to adopt this model by 2030.
Remote patient monitoring (RPM) and connected care management are central to the offering, with proven reductions in hospitalizations, ER visits, and improved pharmaceutical compliance.
Unique selling proposition includes the proprietary wheezo device for respiratory patients and a turnkey solution for all chronic diseases.
Risk-share models and fee-for-service contracts both pursued, with risk-share offering potentially lucrative returns based on shared savings.
RPM revenue per patient per month expected to double in 2025 due to regulatory changes and expanded reimbursement criteria.
Financial Outlook and Operational Targets
Achieved a run-rate ARR of US$5.5M with 40 contracted clients and a current client base of 70,000 patients; sales pipeline includes 350,000 patients.
Current patient programs at 6,500, targeting 30,000 within 12–18 months, with monthly revenues expected to triple in the same period.
Break-even on a cash flow basis anticipated before the end of the calendar year.
Each new contract could add $300,000–$500,000 in annual revenue per existing client through cross-selling and administrative services.
Risk-share contracts typically involve $8–$20 per member per month plus up to 50% of shared savings, with some contracts targeting $10–$15 million in annual savings.
Latest events from Vitasora Health
- Revenue and patient growth accelerate as new AI-driven EMR and stacked models boost efficiency.VHL
Status update19 Mar 2026 - Revenue growth accelerates through policy tailwinds, automation, and expanded patient volume.VHL
Investor presentation18 Mar 2026 - Strong revenue growth and operational momentum offset by continued net losses and going concern risks.VHL
H1 20265 Mar 2026 - Record growth and risk-share focus drive path to profitability and national expansion in 2024.VHL
Status Update2 Feb 2026 - Revenue and billing productivity surged, with CMS changes set to boost 2026 growth.VHL
Q2 2026 TU28 Jan 2026 - RPM revenue set to double by 2026 as patient pipeline and US growth accelerate.VHL
Investor Update16 Jan 2026 - Patient programs and revenue surged, with new contracts and funding supporting U.S. growth.VHL
Q1 2026 TU7 Dec 2025 - Revenue and patient growth accelerate as value-based care and strategic contracts drive expansion.VHL
Status Update10 Nov 2025 - Transformed into a U.S. chronic care leader, acquired Orb Health, and secured $11M for future growth.VHL
H2 202528 Aug 2025